Ferumoxytol

Generic Name: Ferumoxytol

Brand Names: Feraheme

Drug Type: Small Molecule

Chemical Formula: Fe_₃O_₄

CAS Number: 722492-56-0

Unique Ingredient Identifier: G6N3J05W84

Background: Ferumoxytol is an intravenously administered iron preparation indicated in the EU and the US for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) .
...

Indication: This drug is indicated for the treatment of iron deficiency anemia in adult patients who have experienced intolerance to oral iron or have experienced an unsatisfactory response to oral iron or

who have chronic kidney disease (CKD) .

Associated Conditions: Iron Deficiency Anemia (IDA)

Associated Therapies: -

Clinical Trials

Ferumoxytol - Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI

Early Phase 1

Terminated

Conditions: Head and Neck Cancer

Interventions: Procedure: Magnetic Resonance Imaging (MRI)
Drug: Ferumoxytol

First Posted Date: 2013-07-11

Last Posted Date: 2021-09-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT01895829

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Clinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node Imaging

Not Applicable

Completed

Conditions: Cancer of Lymph Node

Interventions: Drug: Feraheme
Procedure: Magnetic Resonance Imaging (MRI)

First Posted Date: 2013-03-21

Last Posted Date: 2020-10-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT01815333

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Phase 1

Completed

Conditions: Metastatic Breast Cancer With Active Brain Metastasis
Solid Tumors
ER/PR Positive Breast Cancer
Triple Negative Breast Cancer

Interventions: Drug: Ferumoxytol
Drug: MM-398

First Posted Date: 2013-01-17

Last Posted Date: 2019-11-27

Lead Sponsor: Ipsen

Target Recruit Count: 45

Registration Number: NCT01770353

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
University of Michighan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

and more 4 locations

Ferumoxytol-enhanced Brain MRI in HIV-associated Neurocognitive Disorders

Phase 1

Completed

Conditions: HIV Dementia

Interventions: Drug: Ferumoxytol

First Posted Date: 2012-08-15

Last Posted Date: 2018-06-01

Lead Sponsor: University of Hawaii

Target Recruit Count: 4

Registration Number: NCT01665846

Locations: 🇺🇸
Hawaii Center for AIDS, Honolulu, Hawaii, United States

Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas

Not Applicable

Withdrawn

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Ferumoxytol

First Posted Date: 2012-08-13

Last Posted Date: 2020-10-19

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT01663090

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States

and more 1 locations

Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

Phase 1

Recruiting

Conditions: Cancer

Interventions: Procedure: WB-DW-MR scan
Procedure: 18-F-FDG PET scan
Drug: Ferumoxytol
Procedure: 18-F-FDG PET/MR scan

First Posted Date: 2012-03-02

Last Posted Date: 2024-11-25

Lead Sponsor: Heike E Daldrup-Link

Target Recruit Count: 75

Registration Number: NCT01542879

Locations: 🇺🇸
Stanford University Cancer Institute, Stanford, California, United States

Imaging of Type 1 Diabetes Progression

Conditions: Type 1 Diabetes

Interventions: Drug: ferumoxytol

First Posted Date: 2012-01-30

Last Posted Date: 2017-04-10

Lead Sponsor: Jason Gaglia

Target Recruit Count: 65

Registration Number: NCT01521520

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Total Dose Infusion of Ferumoxytol(1020mg) in 15 Minutes for Iron Deficiency Anemia

Not Applicable

Completed

Conditions: Iron Deficiency Anemia

Interventions: Drug: ferumoxytol

First Posted Date: 2011-06-16

Last Posted Date: 2014-03-14

Lead Sponsor: Auerbach Hematology Oncology Associates P C

Target Recruit Count: 60

Registration Number: NCT01374919

Locations: 🇺🇸
Auerbach Hematology and Oncology, Baltimore, Maryland, United States

Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI

Phase 2

Completed

Conditions: Rhabdomyosarcoma
Osteomyelitis
Bone Cancer
Chondrosarcoma
Osteosarcoma
Bone Necrosis
Bone Sarcoma
Ewing's Sarcoma

Interventions: Drug: Feraheme
Procedure: Magnetic Resonance Imaging (MRI) scan

First Posted Date: 2011-04-18

Last Posted Date: 2023-12-27

Lead Sponsor: Heike E Daldrup-Link

Target Recruit Count: 32

Registration Number: NCT01336803

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Ferumoxytol

First Posted Date: 2011-02-15

Last Posted Date: 2018-07-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT01296139

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy